Please Wait.....
Report
Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type (Adenovirus, Retrovirus, Adeno-Associated Virus (AAV) , Lentivirus, Plasmids, Others) , By Workflow (Upstream Manufacturing, Downstream Manufacturing) By Application (Antisense & RNAi Therapy, Antisense & RNAi Therapy, Cell Therapy, Vaccinology, Research Applications) By End User (Pharmaceutical & Biopharmaceutical Companies, Research Institutes) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Market Report I 2024-07-01 I 280 Pages I Allied Market Research
Viral Vectors and Plasmid DNA Manufacturing Market
The viral vectors and plasmid DNA manufacturing market was valued at $5.3 billion in 2023 and is projected to reach $34.0 billion by 2033, growing at a CAGR of 20.4% from 2024 to 2033.
Viral vector and plasmid DNA are the crucial components of genetic engineering, utilized for diverse purposes such as gene therapy and vaccine production. A viral vector is a form of molecular vehicle used to transfer genetic information to the cells either through gene expression or integration of genetic material into the cell's DNA. Plasmid DNA is an extrachromosomal circular piece of DNA present in bacteria. It serves as a vector for gene cloning, and gene therapy. The manufacturing of viral vectors and plasmid DNA is accomplished through various methods such as cell culture systems, purification processes, or bacterial fermentation.
Increase in the prevalence of genetic disorders and advancements in technology have facilitated the execution of gene therapies, thereby driving the growth of the viral vectors and plasmid DNA manufacturing market. In addition, rise in R&D activities due to surge in investments & support from government and regulatory agencies such as the Food and Drug administration is boosting the demand for the manufacturing for viral vectors and plasmid DNA. To enhance the scalability of production, the trend of using AI and ML algorithms is gaining prominence. The algorithm helps in identifying the precise requirements and ideal conditions to maximize the production of vectors and plasmid.
However, preventing contamination during manufacturing is challenging as a tiny foreign particle is capable of spoiling the entire production batch. This challenge significantly restrains the growth of the viral vectors and plasmid DNA manufacturing market. In addition, the procurement and maintenance of the equipment required for production is highly expensive, which limits several small-scale firms and laboratories from investing, hence hampering the market growth. Moreover, discrepancies in the regulatory process across the globe restrict the utility of the vectors and plasmid in certain regions. For instance, the European guidelines have mandated the compliance of products with the current good manufacturing practices standards at all stages of production. Contrarily, as per the U.S. Food and Drug Administration, it is acceptable that some materials and all relevant attributes or acceptance criteria remain unknown at stage 1 of product development.
Segment Review
The viral vectors and plasmid DNA manufacturing market is segmented into vector type, workflow, application, end user, and region. On the basis of vector type, the market is divided into adenovirus, retrovirus, adeno-associated virus (AAV), lentivirus, plasmids, and others. Depending on workflow, it is bifurcated into upstream manufacturing and downstream manufacturing. As per application, it is classified into antisense & RNAi therapy, antisense & RNAi therapy, cell therapy, vaccinology, and research applications. According to end user, it is categorized into pharmaceutical & biopharmaceutical companies and research institutes. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of vector type, the adeno-associated virus (AAV) segment dominated the market in 2023.
Depending on workflow, the downstream manufacturing segment accounted for a high market share in 2023.
As per application, the vaccinology segment acquired a high stake in the market in 2023.
According to end user, the research institutes segment was the highest shareholder in 2023.
Region wise, North America was the highest revenue generator in 2023.
Competition Analysis
The leading players operating in the global viral vectors and plasmid DNA manufacturing market include Merck KGaA, Lonza Group AG, FUJIFILM Corporation, thermo fisher scientific, Cobra Biologics, Catalent Inc., WuXi Biologics., TakarBio Inc, Waisman Biomanufacturing, LLC, and Genezen laboratories. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Vector Type
- Adenovirus
- Retrovirus
- Adeno-Associated Virus (AAV)
- Lentivirus
- Plasmids
- Others
By Workflow
- Upstream Manufacturing
- Downstream Manufacturing
By Application
- Antisense RNAi Therapy
- Antisense RNAi Therapy
- Cell Therapy
- Vaccinology
- Research Applications
By End User
- Pharmaceutical Biopharmaceutical Companies
- Research Institutes
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Merck KGaA
- Lonza Group AG
- FUJIFILM Corporation
- Thermo Fisher Scientific Inc.
- Cobra Biologics
- Catalent Inc.
- WuXi Biologics.
- TakarBio Inc
- Waisman Biomanufacturing, LLC
- Genezen laboratories
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: VIRTUAL REHABILITATION AND TELEREHABILITATION SYSTEMS MARKET, BY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Type
4.2. Physical Rehabilitation
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Neuro Rehabilitation
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Cognitive Rehabilitation
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Other Rehabilitations
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
CHAPTER 5: VIRTUAL REHABILITATION AND TELEREHABILITATION SYSTEMS MARKET, BY END USER
5.1. Market Overview
5.1.1 Market Size and Forecast, By End User
5.2. Hospitals
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Care Homes
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Others
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
CHAPTER 6: VIRTUAL REHABILITATION AND TELEREHABILITATION SYSTEMS MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Type
6.2.3. Market Size and Forecast, By End User
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Virtual Rehabilitation and Telerehabilitation Systems Market
6.2.5.1. Market Size and Forecast, By Type
6.2.5.2. Market Size and Forecast, By End User
6.2.6. Canada Virtual Rehabilitation and Telerehabilitation Systems Market
6.2.6.1. Market Size and Forecast, By Type
6.2.6.2. Market Size and Forecast, By End User
6.2.7. Mexico Virtual Rehabilitation and Telerehabilitation Systems Market
6.2.7.1. Market Size and Forecast, By Type
6.2.7.2. Market Size and Forecast, By End User
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Type
6.3.3. Market Size and Forecast, By End User
6.3.4. Market Size and Forecast, By Country
6.3.5. Germany Virtual Rehabilitation and Telerehabilitation Systems Market
6.3.5.1. Market Size and Forecast, By Type
6.3.5.2. Market Size and Forecast, By End User
6.3.6. France Virtual Rehabilitation and Telerehabilitation Systems Market
6.3.6.1. Market Size and Forecast, By Type
6.3.6.2. Market Size and Forecast, By End User
6.3.7. UK Virtual Rehabilitation and Telerehabilitation Systems Market
6.3.7.1. Market Size and Forecast, By Type
6.3.7.2. Market Size and Forecast, By End User
6.3.8. Italy Virtual Rehabilitation and Telerehabilitation Systems Market
6.3.8.1. Market Size and Forecast, By Type
6.3.8.2. Market Size and Forecast, By End User
6.3.9. Spain Virtual Rehabilitation and Telerehabilitation Systems Market
6.3.9.1. Market Size and Forecast, By Type
6.3.9.2. Market Size and Forecast, By End User
6.3.10. Rest of Europe Virtual Rehabilitation and Telerehabilitation Systems Market
6.3.10.1. Market Size and Forecast, By Type
6.3.10.2. Market Size and Forecast, By End User
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Type
6.4.3. Market Size and Forecast, By End User
6.4.4. Market Size and Forecast, By Country
6.4.5. Japan Virtual Rehabilitation and Telerehabilitation Systems Market
6.4.5.1. Market Size and Forecast, By Type
6.4.5.2. Market Size and Forecast, By End User
6.4.6. China Virtual Rehabilitation and Telerehabilitation Systems Market
6.4.6.1. Market Size and Forecast, By Type
6.4.6.2. Market Size and Forecast, By End User
6.4.7. Australia Virtual Rehabilitation and Telerehabilitation Systems Market
6.4.7.1. Market Size and Forecast, By Type
6.4.7.2. Market Size and Forecast, By End User
6.4.8. India Virtual Rehabilitation and Telerehabilitation Systems Market
6.4.8.1. Market Size and Forecast, By Type
6.4.8.2. Market Size and Forecast, By End User
6.4.9. South Korea Virtual Rehabilitation and Telerehabilitation Systems Market
6.4.9.1. Market Size and Forecast, By Type
6.4.9.2. Market Size and Forecast, By End User
6.4.10. Rest of Asia-Pacific Virtual Rehabilitation and Telerehabilitation Systems Market
6.4.10.1. Market Size and Forecast, By Type
6.4.10.2. Market Size and Forecast, By End User
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Type
6.5.3. Market Size and Forecast, By End User
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Virtual Rehabilitation and Telerehabilitation Systems Market
6.5.5.1. Market Size and Forecast, By Type
6.5.5.2. Market Size and Forecast, By End User
6.5.6. Saudi Arabia Virtual Rehabilitation and Telerehabilitation Systems Market
6.5.6.1. Market Size and Forecast, By Type
6.5.6.2. Market Size and Forecast, By End User
6.5.7. South Africa Virtual Rehabilitation and Telerehabilitation Systems Market
6.5.7.1. Market Size and Forecast, By Type
6.5.7.2. Market Size and Forecast, By End User
6.5.8. Rest of LAMEA Virtual Rehabilitation and Telerehabilitation Systems Market
6.5.8.1. Market Size and Forecast, By Type
6.5.8.2. Market Size and Forecast, By End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. Reflexion Health, Inc
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. 270 Vision Ltd
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. CoRehab Srl
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Hinge Health, Inc
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Sword Health, S.A
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. MIRA Rehab Limited
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Bridgeway Senior Healthcare
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Motekforce Link
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. GestureTek Inc.
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Virtualware Group
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
TABLE 1. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 2. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR ADENOVIRUS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 3. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR RETROVIRUS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 4. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR ADENO-ASSOCIATED VIRUS (AAV), BY REGION, 2024 - 2033 ($BILLION)
TABLE 5. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR LENTIVIRUS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 6. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR PLASMIDS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 7. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 8. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 9. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR UPSTREAM MANUFACTURING, BY REGION, 2024 - 2033 ($BILLION)
TABLE 10. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR DOWNSTREAM MANUFACTURING, BY REGION, 2024 - 2033 ($BILLION)
TABLE 11. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 12. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR ANTISENSE RNAI THERAPY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 13. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR ANTISENSE RNAI THERAPY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 14. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR CELL THERAPY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 15. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR VACCINOLOGY, BY REGION, 2024 - 2033 ($BILLION)
TABLE 16. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 17. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 18. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 19. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH INSTITUTES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 20. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY REGION, 2024 - 2033 ($BILLION)
TABLE 21. NORTH AMERICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 22. NORTH AMERICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 23. NORTH AMERICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 24. NORTH AMERICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 25. NORTH AMERICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 26. U.S. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 27. U.S. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 28. U.S. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 29. U.S. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 30. CANADA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 31. CANADA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 32. CANADA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 33. CANADA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 34. MEXICO VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 35. MEXICO VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 36. MEXICO VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 37. MEXICO VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 38. EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 39. EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 40. EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 41. EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 42. EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 43. GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 44. GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 45. GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 46. GERMANY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 47. FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 48. FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 49. FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 50. FRANCE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 51. UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 52. UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 53. UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 54. UK VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 55. ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 56. ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 57. ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 58. ITALY VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 59. SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 60. SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 61. SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 62. SPAIN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 63. REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 64. REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 65. REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 66. REST OF EUROPE VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 67. ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 68. ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 69. ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 70. ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 71. ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 72. JAPAN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 73. JAPAN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 74. JAPAN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 75. JAPAN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 76. CHINA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 77. CHINA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 78. CHINA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 79. CHINA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 80. AUSTRALIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 81. AUSTRALIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 82. AUSTRALIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 83. AUSTRALIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 84. INDIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 85. INDIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 86. INDIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 87. INDIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 88. SOUTH KOREA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 89. SOUTH KOREA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 90. SOUTH KOREA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 91. SOUTH KOREA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 92. REST OF ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 93. REST OF ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 94. REST OF ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 95. REST OF ASIA-PACIFIC VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 96. LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 97. LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 98. LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 99. LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 100. LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 101. BRAZIL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 102. BRAZIL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 103. BRAZIL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 104. BRAZIL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 105. SAUDI ARABIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 106. SAUDI ARABIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 107. SAUDI ARABIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 108. SAUDI ARABIA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 109. SOUTH AFRICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 110. SOUTH AFRICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 111. SOUTH AFRICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 112. SOUTH AFRICA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 113. REST OF LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE, 2024 - 2033 ($BILLION)
TABLE 114. REST OF LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2024 - 2033 ($BILLION)
TABLE 115. REST OF LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2024 - 2033 ($BILLION)
TABLE 116. REST OF LAMEA VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 117. MERCK KGAA: KEY EXECUTIVES
TABLE 118. MERCK KGAA: COMPANY SNAPSHOT
TABLE 119. MERCK KGAA: OPERATING SEGMENTS
TABLE 120. MERCK KGAA: PRODUCT PORTFOLIO
TABLE 121. MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 122. LONZA GROUP AG: KEY EXECUTIVES
TABLE 123. LONZA GROUP AG: COMPANY SNAPSHOT
TABLE 124. LONZA GROUP AG: OPERATING SEGMENTS
TABLE 125. LONZA GROUP AG: PRODUCT PORTFOLIO
TABLE 126. LONZA GROUP AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 127. FUJIFILM CORPORATION: KEY EXECUTIVES
TABLE 128. FUJIFILM CORPORATION: COMPANY SNAPSHOT
TABLE 129. FUJIFILM CORPORATION: OPERATING SEGMENTS
TABLE 130. FUJIFILM CORPORATION: PRODUCT PORTFOLIO
TABLE 131. FUJIFILM CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 132. THERMO FISHER SCIENTIFIC: KEY EXECUTIVES
TABLE 133. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 134. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 135. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 136. THERMO FISHER SCIENTIFIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 137. COBRA BIOLOGICS: KEY EXECUTIVES
TABLE 138. COBRA BIOLOGICS: COMPANY SNAPSHOT
TABLE 139. COBRA BIOLOGICS: OPERATING SEGMENTS
TABLE 140. COBRA BIOLOGICS: PRODUCT PORTFOLIO
TABLE 141. COBRA BIOLOGICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 142. CATALENT INC.: KEY EXECUTIVES
TABLE 143. CATALENT INC.: COMPANY SNAPSHOT
TABLE 144. CATALENT INC.: OPERATING SEGMENTS
TABLE 145. CATALENT INC.: PRODUCT PORTFOLIO
TABLE 146. CATALENT INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 147. WUXI BIOLOGICS.: KEY EXECUTIVES
TABLE 148. WUXI BIOLOGICS.: COMPANY SNAPSHOT
TABLE 149. WUXI BIOLOGICS.: OPERATING SEGMENTS
TABLE 150. WUXI BIOLOGICS.: PRODUCT PORTFOLIO
TABLE 151. WUXI BIOLOGICS.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 152. TAKARBIO INC: KEY EXECUTIVES
TABLE 153. TAKARBIO INC: COMPANY SNAPSHOT
TABLE 154. TAKARBIO INC: OPERATING SEGMENTS
TABLE 155. TAKARBIO INC: PRODUCT PORTFOLIO
TABLE 156. TAKARBIO INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 157. WAISMAN BIOMANUFACTURING, LLC: KEY EXECUTIVES
TABLE 158. WAISMAN BIOMANUFACTURING, LLC: COMPANY SNAPSHOT
TABLE 159. WAISMAN BIOMANUFACTURING, LLC: OPERATING SEGMENTS
TABLE 160. WAISMAN BIOMANUFACTURING, LLC: PRODUCT PORTFOLIO
TABLE 161. WAISMAN BIOMANUFACTURING, LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 162. GENEZEN LABORATORIES: KEY EXECUTIVES
TABLE 163. GENEZEN LABORATORIES: COMPANY SNAPSHOT
TABLE 164. GENEZEN LABORATORIES: OPERATING SEGMENTS
TABLE 165. GENEZEN LABORATORIES: PRODUCT PORTFOLIO
TABLE 166. GENEZEN LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
FIGURE 1. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, 2024 - 2033
FIGURE 2. SEGMENTATION OF VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET, 2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALVIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET
FIGURE 10. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SEGMENTATION, BY VECTOR TYPE
FIGURE 11. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR ADENOVIRUS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 12. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR RETROVIRUS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR ADENO-ASSOCIATED VIRUS (AAV), BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 14. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR LENTIVIRUS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 15. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR PLASMIDS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 16. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 17. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SEGMENTATION, BY WORKFLOW
FIGURE 18. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR UPSTREAM MANUFACTURING, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 19. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR DOWNSTREAM MANUFACTURING, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 20. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SEGMENTATION, BY APPLICATION
FIGURE 21. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR ANTISENSE RNAI THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 22. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR ANTISENSE RNAI THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 23. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR CELL THERAPY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 24. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR VACCINOLOGY, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 25. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 26. GLOBAL VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET SEGMENTATION, BY END USER
FIGURE 27. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 28. VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 29. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 30. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 31. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 32. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 33. COMPETITIVE DASHBOARD
FIGURE 34. COMPETITIVE HEATMAP: VIRAL VECTORS AND PLASMID DNA MANUFACTURING MARKET
FIGURE 35. TOP PLAYER POSITIONING, 2023
FIGURE 36. MERCK KGAA: NET SALES, 2021-2023 ($BILLION)
FIGURE 37. MERCK KGAA: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 38. MERCK KGAA: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 39. LONZA GROUP AG: NET SALES, 2021-2023 ($BILLION)
FIGURE 40. LONZA GROUP AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 41. LONZA GROUP AG: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 42. FUJIFILM CORPORATION: NET SALES, 2021-2023 ($BILLION)
FIGURE 43. FUJIFILM CORPORATION: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 44. FUJIFILM CORPORATION: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 45. THERMO FISHER SCIENTIFIC: NET SALES, 2021-2023 ($BILLION)
FIGURE 46. THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 47. THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 48. COBRA BIOLOGICS: NET SALES, 2021-2023 ($BILLION)
FIGURE 49. COBRA BIOLOGICS: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 50. COBRA BIOLOGICS: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 51. CATALENT INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 52. CATALENT INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 53. CATALENT INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 54. WUXI BIOLOGICS.: NET SALES, 2021-2023 ($BILLION)
FIGURE 55. WUXI BIOLOGICS.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 56. WUXI BIOLOGICS.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 57. TAKARBIO INC: NET SALES, 2021-2023 ($BILLION)
FIGURE 58. TAKARBIO INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 59. TAKARBIO INC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 60. WAISMAN BIOMANUFACTURING, LLC: NET SALES, 2021-2023 ($BILLION)
FIGURE 61. WAISMAN BIOMANUFACTURING, LLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 62. WAISMAN BIOMANUFACTURING, LLC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 63. GENEZEN LABORATORIES: NET SALES, 2021-2023 ($BILLION)
FIGURE 64. GENEZEN LABORATORIES: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 65. GENEZEN LABORATORIES: REVENUE SHARE, BY REGION, 2023 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security